Search clinical trials for: ReFacto

Total 28 results

Cartesian Therapeutics

Recruiting

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Relapse Multiple Myeloma

United States, Turkey
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Bladder Cancer | Carcinoma in Situ of Bladder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Celgene

Completed

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Multiple Myeloma

Austria, Italy, France, Spain, Netherlands, Germany, Greece, United Kingdom
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Withdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (RESIST NAIVE)

Severe Hemophilia A
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Lymphoma

United States
Pfizer

Completed

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting

Hemophilia A

Spain, France, Turkey, Netherlands, Germany, Italy, Ukraine
Pfizer

Completed

Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study

Hemophilia A | Hemophilia B
Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
Shanghai Jiao Tong University School of Medicine

Completed

Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML

Acute Leukemia

China
Pfizer

Completed

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

Hemophilia A

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
Pfizer

Completed

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Hemophilia A

Spain, Finland, Serbia, Georgia, Italy, Romania, Sweden, Turkey, Ukraine
Shanghai Jiao Tong University School of Medicine

Unknown

Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL

Lymphoblastic Leukemia, Acute, Adult

China
Chinese PLA General Hospital

Unknown

Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors (CART-HER-2)

Advanced HER-2 Positive Solid Tumors | Chemotherapy Refactory | HER-2 Antibody Inhibitor Therapy Refactory

China
Pfizer

Terminated

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Hemophilia A

Netherlands, Spain, Greece, Italy, France, Belgium, Germany, Austria, Sweden, Hungary, Finland, United Kingdom, Denmark, Romania
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto in Hemophilia A

Hemophilia A
Pfizer

Completed

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Hemophilia A

United Kingdom, Hungary, Bulgaria
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery

Hemophilia A

United States, New Zealand, Australia, Hungary, Sweden, Austria, Poland, Romania
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Refacto For Pharmacovigilance

Hemophilia A

Germany, Austria
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto AF in Severe Hemophilia A

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A

Hemophilia A

Poland, Belgium, France, Italy, Spain, United States, Australia, Netherlands, New Zealand, Sweden, Germany, Finland, Hungary
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

Hemophilia A

United States
University of Aarhus

Completed

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

Hemophilia A

Denmark

Search clinical trials for: ReFacto

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Equatorial Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations